Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Purpose
This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions
- Anal Basaloid Carcinoma
- Anal Canal Cloacogenic Carcinoma
- Anal Margin Squamous Cell Carcinoma
- Stage IIB Anal Cancer AJCC v8
- Stage III Anal Cancer AJCC v8
- Stage IIIA Anal Cancer AJCC v8
- Stage IIIB Anal Cancer AJCC v8
- Stage IIIC Anal Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients must have histologically proven stage IIB (T3N0M0 only), IIIA (T2N1M0), IIIB (T4N0M0), or IIIC (T3N1M0, T4N1M0) invasive squamous cell carcinoma of the anus or anorectum, according to the American Joint Committee on Cancer (AJCC) 8th edition; this may include tumors of non-keratinizing histology such as basaloid, transitional cell, or cloacogenic histology; individuals with squamous cell carcinoma of the anal margin are eligible if there is evidence of extension of the primary tumor into the anal canal - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients must have hemoglobin levels of > 9 g/dL (within 2 weeks prior to registration) - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patient must have a platelet count of > 100,000/mm^3 (within 2 weeks prior to registration) - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patient's absolute neutrophil count (ANC) level must be > 1500/mm^3 (within 2 weeks prior to registration) - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Serum creatinine must be =< 1.5 X upper limit of normal (ULN) (within 2 weeks prior to registration) - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Total bilirubin must be < 2 X ULN (within 2 weeks prior to registration) - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normal (within 2 weeks prior to registration) - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Albumin >= 3.0 g/dL (within 2 weeks prior to registration) - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients known to be human immunodeficiency virus (HIV)+ are permitted; patients with CD4 > 200 and serum HIV viral load of < 200 copies/mm^3 are eligible, and in addition: - Participants must be purified protein derivative (PPD) negative; alternatively, the QuantiFERON-tuberculosis (TB) Gold In-Tube (QFT-GIT) assay (Cellestis Limited, Carnegie, Australia) can be used; an individual is considered positive for M. tuberculosis infection if the IFN-gamma response to TB antigens is above the test cut-off (after subtracting the background IFN-gamma response in the negative control); the result must be obtained within 20 weeks prior to enrollment; PPD positive (or Quantiferon assay positive) participants are permitted if prophylaxis has been completed prior to enrollment - No history of acquired immune deficiency syndrome (AIDS)-related complications within past year other than a history of low CD4+ T-cell count > 200/mm^3 prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to chemoradiotherapy and should not be used as an exclusion criterion if low - Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the anal cancer - Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 12 weeks following enrollment - Patient must have =< grade 2 diarrhea (participants with grade 1 diarrhea are eligible provided stool for ova/parasites and stool cryptosporidium studies are negative; - NOTE: HIV testing is not required for eligibility - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: For patients registering prior to start of chemoradiotherapy, baseline scans must have been completed within 4 weeks prior to registration - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Women of child bearing potential and sexually active males must use accepted and effective method(s) of contraception and/or abstain from sexual intercourse while on protocol treatment and for at least 5 months after the last dose of nivolumab (for female patients) and for at least 7 months after the last dose of nivolumab (for male patients) - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Any surgery must have been completed >= 4 weeks prior to starting study treatment - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: No uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: No prior treatment with an immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 monoclonal antibody) - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: No patients with immunodeficiency or receiving systemic steroid therapy equivalent to > 10 mg prednisone per day or any other form of immunosuppressive therapy within 7 days prior to Step 1 registration; topical corticosteroid or occasional inhaled corticosteroids are allowed - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: No live vaccines within 30 days prior to registration; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed - NOTE: no live vaccines may be administered while participating in the trial - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Previously irradiated patients (Arm S) must have received radiation per National Comprehensive Cancer Network guidelines; radiation therapy delivered on protocol (Arm T) will be reviewed - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients will be registered within 63 days following completion of standard chemoradiation for anal cancer; standard chemoradiation therapy is as defined - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must have histologically proven stage IIB (T3N0M0 only), IIIA (T2N1M0), IIIB (T4N0M0), or IIIC (T3N1M0, T4N1M0) invasive squamous cell carcinoma of the anus or anorectum, according to the AJCC 8th edition; this may include tumors of non-keratinizing histology such as basaloid, transitional cell, or cloacogenic histology; individuals with squamous cell carcinoma of the anal margin are eligible if there is evidence of extension of the primary tumor into the anal canal - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must have received at least 54 gray (Gy) of radiation to the PTVp (primary) and 45 Gy to PTVn (elective nodal region) for the treatment of the anal cancer - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must have ECOG performance status of 0-2 - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must have hemoglobin levels of > 10 g/dL (within 2 weeks prior to registration) - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient must have a platelet count of > 100,000/mm^3 (within 2 weeks prior to registration) - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient's ANC level must be > 1500/mm^3 (within 2 weeks prior to registration) - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Serum creatinine must be =< 1.5 X ULN (within 2 weeks prior to registration) - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Total bilirubin must be < 2 X ULN (within 2 weeks prior to registration) - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: AST (SGOT)/ALT (SGPT) =< 2.5 X institutional upper limit of normal (within 2 weeks prior to registration) - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Albumin >= 3.0 g/dL (within 2 weeks prior to registration) - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients known to be human immunodeficiency virus (HIV)+ patients with CD4 > 200 and serum HIV viral load of < 200 copies/mm^3 are eligible; in addition: - Participants must be PPD negative; alternatively, the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay (Cellestis Limited, Carnegie, Australia) can be used; an individual is considered positive for M. tuberculosis infection if the IFN-gamma response to TB antigens is above the test cut-off (after subtracting the background IFN-gamma response in the negative control); the result must be obtained within 20 weeks prior to enrollment; PPD positive (or Quantiferon assay positive) participants are permitted if prophylaxis has been completed prior to enrollment; NOTE: If patient completed chemoradiation on Step 1, PPD testing does not need to be performed again - No history of AIDS-related complications within past year other than a history of low CD4+ T-cell count > 200/mm^3 prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to chemoradiotherapy should not be used as an exclusion criterion if low - Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the anal cancer - Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 12 weeks following enrollment - Patient must have =< grade 2 diarrhea (participants with grade 1 diarrhea are eligible provided stool for ova/parasites and stool cryptosporidium studies are negative) - NOTE: HIV testing is not required for eligibility - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Scans done within 4 weeks of randomization to Step 2 - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient must have recovered from all toxicities associated with chemoradiotherapy for anal cancer, to grade =< 1 with the exception of alopecia - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Women of child bearing potential and sexually active males must use accepted and effective method(s) of contraception and/or abstain from sexual intercourse while on protocol treatment and for at least 5 months after the last dose of nivolumab (for female patients) and for at least 7 months after the last dose of nivolumab (for male patients) - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No prior treatment with an immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 monoclonal antibody) - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No patients with immunodeficiency or receiving systemic steroid therapy equivalent to > 10 mg prednisone per day or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication; topical corticosteroid or occasional inhaled corticosteroids are allowed - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed
Exclusion Criteria
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: For patients registering to Arm T, patients must not have received prior chemoradiotherapy for anal cancer - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients with an allogenic bone marrow/stem, cell or solid organ transplant are excluded - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Women MUST NOT be pregnant or breast-feeding due to the potential teratogenic harm or abortifacient effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used; all patients must also not expect to conceive or father children from study registration and throughout their time on study treatment; for female patients this must continue until at least 5 months after the last dose of nivolumab and for male patients until at least 7 months after the last dose of nivolumab; all females of child bearing potential must have a serum or urine pregnancy test to rule out pregnancy within 2 weeks prior to registration; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients will be excluded if they have a T1 or M1, and T2N0 cancer - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients must not have had prior potentially curative surgery (abdominal, peritoneal resection) for carcinoma of the anus - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Participants may not be receiving any other standard anti-cancer therapy or experimental agent concurrently with the study drugs - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Individuals with a history of a different malignancy are ineligible except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence; individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin - REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patient must not have active autoimmune disease in the past 2 years - NOTE: This does not include patients with autoimmune disease controlled by medication, such as hypothyroidism; this eligibility includes only patients with endocrine disease controlled b
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Arm A (nivolumab) |
Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. |
|
Other Arm B (clinical observation) |
Patients undergo observation for up to 6 months. |
|
Recruiting Locations
Birmingham, Alabama 35233
Fairbanks, Alaska 99701
Goodyear, Arizona 85338
Site Public Contact
623-207-3000
Phoenix, Arizona 85054
Site Public Contact
855-776-0015
Scottsdale, Arizona 85259
Site Public Contact
855-776-0015
Jonesboro, Arkansas 72401
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Anaheim, California 92806
Antioch, California 94531
Auburn, California 95602
Baldwin Park, California 91706
Bellflower, California 90706
Berkeley, California 94704
Chico, California 95926
Site Public Contact
530-332-3808
Clovis, California 93611
Site Public Contact
559-387-1827
Dublin, California 94568
Site Public Contact
877-642-4691
Fontana, California 92335
Fremont, California 94538
Fremont, California 94538
Fresno, California 93720
Fresno, California 93720
Harbor City, California 90710
Irvine, California 92618
Los Angeles, California 90027
Los Angeles, California 90034
Modesto, California 95355
Modesto, California 95356
Mountain View, California 94040
Oakland, California 94611
Oakland, California 94611
Ontario, California 91761
Orange, California 92868
Site Public Contact
714-734-6220
Palo Alto, California 94301
Palo Alto, California 94304
Panorama City, California 91402
Rancho Cordova, California 95670
Rancho Mirage, California 92270
Site Public Contact
760-834-3798
Redwood City, California 94063
Richmond, California 94801
Riverside, California 92505
Rohnert Park, California 94928
Roseville, California 95661
Roseville, California 95661
Roseville, California 95678
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95817
Site Public Contact
916-734-3089
Sacramento, California 95823
Sacramento, California 95823
San Diego, California 92120
San Francisco, California 94115
San Francisco, California 94115
San Jose, California 95119
San Leandro, California 94577
San Marcos, California 92078
San Mateo, California 94401
San Rafael, California 94903
Santa Clara, California 95051
Santa Cruz, California 95065
Santa Rosa, California 95403
South San Francisco, California 94080
South San Francisco, California 94080
Stockton, California 95210
Sunnyvale, California 94086
Vacaville, California 95688
Vallejo, California 94589
Vallejo, California 94589
Walnut Creek, California 94596
Woodland Hills, California 91367
Boulder, Colorado 80301
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Colorado Springs, Colorado 80920
Site Public Contact
719-364-6700
Lafayette, Colorado 80026
Lone Tree, Colorado 80124
Thornton, Colorado 80260
Frankford, Delaware 19945
Newark, Delaware 19713
Newark, Delaware 19713
Rehoboth Beach, Delaware 19971
Washington, District of Columbia 20037
Site Public Contact
202-741-2981
Altamonte Springs, Florida 32701
Site Public Contact
407-303-2200
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Fort Lauderdale, Florida 33308
Site Public Contact
954-267-7750
Gainesville, Florida 32610
Miami Beach, Florida 33140
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33176
Site Public Contact
305-243-2647
Orlando, Florida 32803
Pensacola, Florida 32504
Atlanta, Georgia 30303
Site Public Contact
404-489-9164
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Decatur, Georgia 30033
Site Public Contact
404-321-6111
Savannah, Georgia 31405
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83686
Nampa, Idaho 83686
Twin Falls, Idaho 83301
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Chicago, Illinois 60611
Chicago, Illinois 60612
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Decatur, Illinois 62526
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Galesburg, Illinois 61401
Site Public Contact
309-344-2831
Kewanee, Illinois 61443
Macomb, Illinois 61455
Maywood, Illinois 60153
Site Public Contact
708-226-4357
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61636
Peoria, Illinois 61637
Peru, Illinois 61354
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Carmel, Indiana 46032
Indianapolis, Indiana 46202
Indianapolis, Indiana 46237
Site Public Contact
317-528-7060
Lafayette, Indiana 47905
Mooresville, Indiana 46158
Site Public Contact
317-834-3603
Terre Haute, Indiana 47804
Site Public Contact
812-238-7394
Bettendorf, Iowa 52722
Clive, Iowa 50325
Clive, Iowa 50325
Creston, Iowa 50801
Des Moines, Iowa 50309
Site Public Contact
515-282-2921
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
West Des Moines, Iowa 50266
Olathe, Kansas 66061
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Westwood, Kansas 66205
Louisville, Kentucky 40202
Site Public Contact
502-562-3429
Metairie, Louisiana 70006
Baltimore, Maryland 21204
Site Public Contact
443-849-3706
Boston, Massachusetts 02215
Site Public Contact
617-667-9925
Worcester, Massachusetts 01655
Ann Arbor, Michigan 48106
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Brighton, Michigan 48114
Canton, Michigan 48188
Canton, Michigan 48188
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Dearborn, Michigan 48124
Site Public Contact
248-551-7695
Detroit, Michigan 48202
Detroit, Michigan 48236
East China Township, Michigan 48054
Farmington Hills, Michigan 48336
Site Public Contact
248-551-7695
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grosse Pointe Woods, Michigan 48236
Grosse Pointe Woods, Michigan 48236
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Lansing, Michigan 48912
Livonia, Michigan 48154
Livonia, Michigan 48154
Macomb, Michigan 48044
Muskegon, Michigan 49444
Norton Shores, Michigan 49444
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Reed City, Michigan 49677
Royal Oak, Michigan 48073
Site Public Contact
248-551-7695
Saginaw, Michigan 48601
Saginaw, Michigan 48604
Saint Joseph, Michigan 49085
Southfield, Michigan 48075
Sterling Heights, Michigan 48312
Tawas City, Michigan 48764
Traverse City, Michigan 49684
Troy, Michigan 48085
Site Public Contact
248-551-7695
Warren, Michigan 48093
Warren, Michigan 48093
Wyoming, Michigan 49519
Ypsilanti, Michigan 48106
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Fridley, Minnesota 55432
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Minneapolis, Minnesota 55415
Robbinsdale, Minnesota 55422
Rochester, Minnesota 55905
Site Public Contact
855-776-0015
Sandstone, Minnesota 55072
Stillwater, Minnesota 55082
Virginia, Minnesota 55792
Grenada, Mississippi 38901
New Albany, Mississippi 38652
Oxford, Mississippi 38655
Southhaven, Mississippi 38671
Cape Girardeau, Missouri 63703
Creve Coeur, Missouri 63141
Saint Louis, Missouri 63110
Saint Louis, Missouri 63129
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Saint Peters, Missouri 63376
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Washington, Missouri 63090
Site Public Contact
636-390-1600
Billings, Montana 59101
Great Falls, Montana 59405
Grand Island, Nebraska 68803
Kearney, Nebraska 68847
Omaha, Nebraska 68114
Site Public Contact
402-354-5144
Las Vegas, Nevada 89102
Las Vegas, Nevada 89148
Reno, Nevada 89502
Basking Ridge, New Jersey 07920
Site Public Contact
212-639-7592
Middletown, New Jersey 07748
Site Public Contact
212-639-7592
Montvale, New Jersey 07645
Site Public Contact
212-639-7592
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Voorhees, New Jersey 08043
Site Public Contact
856-247-7395
Albuquerque, New Mexico 87102
Bronx, New York 10461
Bronx, New York 10461
Bronx, New York 10467
Buffalo, New York 14263
Commack, New York 11725
Site Public Contact
212-639-7592
Glens Falls, New York 12801
Site Public Contact
518-926-6700
Harrison, New York 10604
Site Public Contact
212-639-7592
New York, New York 10029
New York, New York 10065
Site Public Contact
212-639-7592
Uniondale, New York 11553
Site Public Contact
212-639-7592
Albemarle, North Carolina 28002
Site Public Contact
800-804-9376
Charlotte, North Carolina 28203
Site Public Contact
800-804-9376
Charlotte, North Carolina 28210
Site Public Contact
980-442-2000
Charlotte, North Carolina 28211
Site Public Contact
980-442-2000
Charlotte, North Carolina 28262
Site Public Contact
800-804-9376
Charlotte, North Carolina 28277
Site Public Contact
800-804-9376
Clinton, North Carolina 28328
Concord, North Carolina 28025
Site Public Contact
800-804-9376
Gastonia, North Carolina 28054
Site Public Contact
800-804-9376
Goldsboro, North Carolina 27534
Hendersonville, North Carolina 28791
Jacksonville, North Carolina 28546
Lincolnton, North Carolina 28092
Site Public Contact
800-804-9376
Monroe, North Carolina 28112
Site Public Contact
980-442-2000
Raleigh, North Carolina 27607
Site Public Contact
919-784-7209
Raleigh, North Carolina 27607
Site Public Contact
919-784-7209
Raleigh, North Carolina 27614
Site Public Contact
919-784-7209
Winston-Salem, North Carolina 27157
Site Public Contact
336-713-6771
Bismarck, North Dakota 58501
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Minot, North Dakota 58701
Site Public Contact
800-862-0005
Beachwood, Ohio 44122
Belpre, Ohio 45714
Chardon, Ohio 44024
Chillicothe, Ohio 45601
Cincinnati, Ohio 45219
Cincinnati, Ohio 45220
Cleveland, Ohio 44106
Columbus, Ohio 43210
Columbus, Ohio 43214
Columbus, Ohio 43214
Columbus, Ohio 43215
Columbus, Ohio 43219
Columbus, Ohio 43228
Delaware, Ohio 43015
Delaware, Ohio 43015
Elyria, Ohio 44035
Mansfield, Ohio 44903
Marietta, Ohio 45750
Marion, Ohio 43302
Mentor, Ohio 44060
Middleburg Heights, Ohio 44130
Newark, Ohio 43055
Parma, Ohio 44129
Portsmouth, Ohio 45662
Ravenna, Ohio 44266
Sandusky, Ohio 44870
Wadsworth, Ohio 44281
West Chester, Ohio 45069
Westlake, Ohio 44145
Westlake, Ohio 44145
Zanesville, Ohio 43701
Oklahoma City, Oklahoma 73104
Tulsa, Oklahoma 74146
Site Public Contact
918-505-3200
Bend, Oregon 97701
Clackamas, Oregon 97015
Newberg, Oregon 97132
Ontario, Oregon 97914
Portland, Oregon 97213
Portland, Oregon 97225
Portland, Oregon 97227
Portland, Oregon 97239
Allentown, Pennsylvania 18103
Bethlehem, Pennsylvania 18017
Bryn Mawr, Pennsylvania 19010
Collegeville, Pennsylvania 19426
Exton, Pennsylvania 19341
Harrisburg, Pennsylvania 17101
Harrisburg, Pennsylvania 17109
Media, Pennsylvania 19063
Paoli, Pennsylvania 19301
Philadelphia, Pennsylvania 19104
Site Public Contact
800-474-9892
Philadelphia, Pennsylvania 19107
Site Public Contact
215-955-6084
Philadelphia, Pennsylvania 19111
Site Public Contact
215-728-4790
Philadelphia, Pennsylvania 19140
Site Public Contact
215-728-2983
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
West Reading, Pennsylvania 19611
Site Public Contact
610-988-9323
Wilkes-Barre, Pennsylvania 18711
Willow Grove, Pennsylvania 19090
Site Public Contact
215-481-2402
Wynnewood, Pennsylvania 19096
Boiling Springs, South Carolina 29316
Easley, South Carolina 29640
Georgetown, South Carolina 29440
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29615
Greer, South Carolina 29650
Rock Hill, South Carolina 29730
Site Public Contact
800-804-9376
Rock Hill, South Carolina 29732
Site Public Contact
800-804-9376
Seneca, South Carolina 29672
Spartanburg, South Carolina 29303
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Collierville, Tennessee 38017
Memphis, Tennessee 38120
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Houston, Texas 77030
Farmington, Utah 84025
Salt Lake City, Utah 84106
Salt Lake City, Utah 84112
Berlin, Vermont 05602
Site Public Contact
802-225-5400
Burlington, Vermont 05401
Burlington, Vermont 05405
Richmond, Virginia 23298
South Hill, Virginia 23970
Aberdeen, Washington 98520
Bellingham, Washington 98225
Lacey, Washington 98503
Renton, Washington 98055
Seattle, Washington 98109
Site Public Contact
800-804-8824
Seattle, Washington 98109
Site Public Contact
800-804-8824
Seattle, Washington 98195
Site Public Contact
800-804-8824
Walla Walla, Washington 99362
Charleston, West Virginia 25304
Site Public Contact
304-388-9944
Morgantown, West Virginia 26506
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Burlington, Wisconsin 53105
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54301
Site Public Contact
920-435-8326
Green Bay, Wisconsin 54311
Kenosha, Wisconsin 53142
La Crosse, Wisconsin 54601
Marinette, Wisconsin 54143
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53233
Minocqua, Wisconsin 54548
New Richmond, Wisconsin 54017
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53406
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54482
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
Weston, Wisconsin 54476
More Details
- NCT ID
- NCT03233711
- Status
- Recruiting
- Sponsor
- National Cancer Institute (NCI)
Detailed Description
PRIMARY OBJECTIVE: I. To evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) compared with observation in patients with high risk anal carcinoma. SECONDARY OBJECTIVES: I. To compare nivolumab following combined modality therapy (CMT) with observation in patients with high risk anal carcinoma with regard to: Ia. Objective response rate (complete [CR] and partial [PR]), stable disease and progression. Ib. Severe toxicity interval. Ic. Colostomy-free survival. Id. Overall survival. Ie. Toxicity. OUTLINE: Patients who received standard CMT are randomized to 1 of 2 arms. ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. ARM B: Patients undergo observation for up to 6 months. After completion of study treatment, patients are followed up at 6 weeks, every 3 months for 2 years, and then every 6 months for 3 years.